Plain-English translation of NCT07106814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called Meta10-TIL, which uses special immune cells called tumor-infiltrating lymphocytes. Doctors take these cells from your tumor, grow millions of them in the laboratory, and then put them back into your body to fight the cancer. The study will check whether this treatment is safe and whether it helps people with advanced cancers including cervical cancer, liver cancer, and breast cancer.
Standard treatments for advanced cancers don't work for everyone, and some people can't tolerate the side effects. This trial is exploring whether using your own immune cells, specially trained and multiplied in the lab, could offer a new option for people whose cancers have stopped responding to existing treatments.
You likely qualify if…
You likely don't qualify if…
First, you will receive chemotherapy medication (cyclophosphamide and fludarabine) to prepare your body. Then, doctors will infuse the grown immune cells back into your body on day 0. You will have multiple follow-up visits where doctors will check how you are responding to the treatment, monitor you for side effects, and perform scans and blood tests to measure whether the cancer is shrinking. The study will track your health and survival over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Anhui Provincial Hospital
Collaborators
Leman Biotech Co., Ltd.
Enrollment target
~36 participants
Started
August 2025
Primary completion
August 2027
Age range
19 Years – 70 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fanzheng Meng, Ph.D
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.